Literature DB >> 7504522

Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis.

J A Macoska1, M A Micale, W A Sakr, P D Benson, S R Wolman.   

Abstract

The genetic alterations that underlie prostate tumorigenesis are assumed to comprise gain or loss of specific chromosomal regions, whole chromosomes, or sequence-specific mutations. Existing data have not demonstrated clear specificity of whole chromosome or regional chromosomal gain or loss that characterizes entire individual malignant lesions, or all malignant lesions, within a cancerous prostate. We have analyzed tissues from 13 patients for target sequences by using PCR and FISH techniques on paired malignant or prostatic intraepithelial neoplastic (PIN) and benign samples (usually from different areas of the same paraffin section). We exercised stringent histologic control over these samples by examining small (< 5 mm2), discrete regions of sectioned benign, malignant, and PIN tissue. The same histologic region was examined on serial sections by FISH and PCR analysis. The tissues were examined for numerical aberrations involving chromosomes 4 (as a control), 7, 8, 10, and the Y by FISH analysis, and for gain or loss of chromosome 7 and chromosomal arms 8p, 10q, and Yp by PCR analysis. The concurrent application of PCR and FISH to microdissected prostatic tissues yielded evidence of higher frequencies of genetic aberration in prostate cancers than those found with either method alone or by other approaches. These results indicate the power of simultaneous genetic assays that are closely linked to specific tumor histology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504522     DOI: 10.1002/gcc.2870080205

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  10 in total

1.  Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.

Authors:  S F Huang; S Xiao; A A Renshaw; K R Loughlin; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  The effectiveness of imaging modalities in clinical staging of localized prostatic carcinoma.

Authors:  T Tarcan; L Türkeri; T Biren; S Küllü; N Gürmen; A Akdaş
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

3.  Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization.

Authors:  T Visakorpi; E Hyytinen; A Kallioniemi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

Review 4.  Review of allelic loss and gain in prostate cancer.

Authors:  G S Bova; W B Isaacs
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

Review 6.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

7.  Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas.

Authors:  D Schofield; D C West; D C Anthony; R Marshal; J Sklar
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 8.  The Genomics of Prostate Cancer: A Historic Perspective.

Authors:  Mark A Rubin; Francesca Demichelis
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

9.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Authors:  P Koivisto; E Hyytinen; C Palmberg; T Tammela; T Visakorpi; J Isola; O P Kallioniemi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

10.  Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage.

Authors:  A J Russell; J Sibbald; H Haak; W N Keith; A M McNicol
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.